Medication info
Lyrica CR Extended-Release Tablets 165 mg (Pregabalin)

Lyrica CR Extended-Release Tablets 165 mg (Pregabalin)

Prescription medicationTabletOral
Ingredient · strength
Pregabalin›165mg / 1 tablet
Manufacturer / importer
Viatris
Appearance
Pale orange almond-shaped film-coated extended-release tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201802990 · Approved 2018.07.18 · Insurance code 073400260

Summary

Main use
Treatment of peripheral neuropathic pain in adults
Who takes it
Adults · Children
Adult dose
This medicine is administered once daily after the evening meal. An initial dose of 165 mg once daily may be administered. Based on the response and tolerability of the individual patient, the dose may be increased to 330 mg once daily after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 660 mg daily. When switching from Lyrica Capsules to Lyrica CR Extended-Release Tablets, take the morning dose of Lyrica Capsules as prescribed on the day of the switch, and begin taking Lyrica CR Extended-Release Tablets after the evening meal. 75 mg/day → 82.5 mg/day 150 mg/day → 165 mg/day 225 mg/day → 247.5 mga/day 300 mg/day → 330 mg/day 450 mg/day → 495 mgb/day 600 mg/day → 660 mgc/day a. 247.5 mg= 3×82.5 mg tablets administered once daily b. 495 mg= 3×165 mg tablets administered once daily c. 660 mg=2×330 mg tablets administered once daily If treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. Use of this medicine is not recommended in patients with creatinine clearance below 30 mL/min or in patients undergoing hemodialysis. These patients should receive Lyrica Capsules. ≥60 mL/min: 165 mg, 330 mg, 495a mg, 660b mg; once daily 30-60 mL/min: 82.5 mg, 165 mg, 247.5c mg, 330 mg; once daily <30 or hemodialysis: administer Lyrica Capsules a. 495 mg= 3×165 mg tablets administered once daily b. 660 mg= 2×330 mg tablets administered once daily c. 247.5 mg=3×82.5 mg tablets administered once daily Dose adjustment is not required in patients with hepatic impairment. 65 years of age and older: Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescents aged 12-17 years: Use is not recommended because there are insufficient safety and efficacy data.

Ingredients

Importer
Viatris

Efficacy & effects

Treatment of peripheral neuropathic pain in adults

  • Peripheral neuropathic pain
View approved original text

This medication is used to treat pain caused by peripheral neuropathy in adults.

How to take

Adult dose

This medicine is administered once daily after the evening meal. An initial dose of 165 mg once daily may be administered. Based on the response and tolerability of the individual patient, the dose may be increased to 330 mg once daily after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 660 mg daily. When switching from Lyrica Capsules to Lyrica CR Extended-Release Tablets, take the morning dose of Lyrica Capsules as prescribed on the day of the switch, and begin taking Lyrica CR Extended-Release Tablets after the evening meal. 75 mg/day → 82.5 mg/day 150 mg/day → 165 mg/day 225 mg/day → 247.5 mga/day 300 mg/day → 330 mg/day 450 mg/day → 495 mgb/day 600 mg/day → 660 mgc/day a. 247.5 mg= 3×82.5 mg tablets administered once daily b. 495 mg= 3×165 mg tablets administered once daily c. 660 mg=2×330 mg tablets administered once daily If treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. Use of this medicine is not recommended in patients with creatinine clearance below 30 mL/min or in patients undergoing hemodialysis. These patients should receive Lyrica Capsules. ≥60 mL/min: 165 mg, 330 mg, 495a mg, 660b mg; once daily 30-60 mL/min: 82.5 mg, 165 mg, 247.5c mg, 330 mg; once daily <30 or hemodialysis: administer Lyrica Capsules a. 495 mg= 3×165 mg tablets administered once daily b. 660 mg= 2×330 mg tablets administered once daily c. 247.5 mg=3×82.5 mg tablets administered once daily Dose adjustment is not required in patients with hepatic impairment. 65 years of age and older: Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescents aged 12-17 years: Use is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so careful monitoring for depression, mood changes, or abnormal behavior is required during treatment. Do not use if allergic to any components of this medication. Diabetic patients may have difficulty controlling blood sugar due to weight gain, which may require adjustments in blood sugar medication dosages. If serious allergic reactions such as angioedema occur, stop taking the medication immediately and inform your healthcare provider. Elderly patients may experience dizziness, drowsiness, or confusion, so special caution is needed when starting this medication. Visual disturbances such as blurred vision may occur, and if symptoms persist, consult a physician. Suddenly stopping this medication may lead to withdrawal symptoms such as insomnia, headache, and anxiety; therefore, it should be gradually reduced following a doctor's instructions. Patients with a history of mental illness or substance abuse may be at risk for drug dependence, so caution is advised. Patients with impaired kidney function should have their dosages of this medication adjusted, and it is not recommended for patients on dialysis. Patients with heart conditions should be cautious, as cardiovascular problems such as congestive heart failure may occur while taking this medication. There is a risk of respiratory depression if taken in combination with central nervous system depressants or opioid analgesics; caution is needed when taken together. During early pregnancy, there is a risk of fetal malformation; therefore, it is advisable for pregnant women not to take this medication and for women of childbearing age to use effective contraception methods. This medication may be excreted in breast milk, so consider stopping breastfeeding or discontinuing the medication while nursing. Dizziness or drowsiness may occur while taking this medication, so it is safe to avoid driving or operating hazardous machinery. Severe skin reactions may rarely occur, so if symptoms such as rash, blisters, or mucosal damage appear, discontinue use immediately and consult your healthcare provider. Overdose may cause confusion, drowsiness, seizures, etc., and appropriate treatment such as dialysis should be received if necessary. This medication should be kept out of reach of children and should not be transferred to other containers.

Side effects

  • Suicidal impulses
  • suicidal behavior
  • depression
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper airway swelling
  • dizziness
  • drowsiness
  • loss of consciousness
Show 187 more
  • confusion
  • mental disorders
  • blurred vision
  • nausea
  • diarrhea
  • vomiting
  • peripheral edema
  • weight gain
  • dry mouth
  • constipation
  • fatigue
  • rhinitis
  • urinary tract infection
  • upper respiratory infection
  • bronchitis
  • viral respiratory infection
  • sinusitis
  • viral gastroenteritis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • increased appetite
  • back pain
  • arthralgia
  • joint swelling
  • headache
  • balance disorder
  • insomnia
  • erectile dysfunction
  • cough
  • rash
  • contact dermatitis
  • neutropenia
  • confusion
  • difficulty with spatial orientation
  • hypersensitivity
  • euphoria
  • decreased libido
  • depersonalization
  • paraphilia
  • restlessness
  • agitation
  • mood disturbance
  • emotional lability
  • emotional blunting
  • difficulty finding the right term
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • motor coordination abnormalities
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • drowsiness
  • cognitive impairment
  • nystagmus
  • speech impairment
  • myoclonic jerks
  • reflex reduction
  • movement disorders
  • psychomotor agitation
  • position-related dizziness
  • sensory hyperesthesia
  • burning sensation
  • intention tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory abnormalities
  • loss of taste
  • writing impairment
  • indirect vision loss
  • visual impairment
  • visual field loss
  • photophobia
  • dry eyes
  • eyelid swelling
  • vision reduction
  • ocular pain
  • eye fatigue
  • increased tear secretion
  • ocular irritation
  • mydriasis
  • during vibration
  • changes in depth perception
  • strabismus
  • brightness of vision
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • bradycardia
  • atrial tachycardia
  • arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • abdominal distention
  • hypersalivation
  • gastroesophageal reflux
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • myalgia
  • muscle twitching
  • neck pain
  • muscle stiffness
  • rhabdomyolysis
  • urination disturbances
  • urinary incontinence
  • decreased urination
  • renal failure
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • gynecomastia
  • fatigue
  • weakness
  • decreased libido
  • sleep disorders
  • ataxia
  • dysarthria
  • sensory abnormalities
  • memory impairment
  • attention deficit
  • constipation
  • gastrointestinal disorders
  • hematochezia
  • increased BUN
  • dysuria
  • exacerbated seizures
  • tinnitus
  • skin disorders
  • palpitations
  • weakness syndrome
  • heat sensation
  • deep vein thrombosis
  • pneumonia
  • thalamic infarction
  • osteoarthritis
  • bursitis
  • anemia
  • oral sensory abnormalities
  • bruising
  • diabetic retinopathy
  • atrial fibrillation
  • hyperhidrosis
  • thyroid nodule
  • spinal stenosis
  • musculoskeletal discomfort
  • limb discomfort
  • abdominal pain
  • upper abdominal pain
  • eyelid swelling
  • cataract
  • paralysis (facial paralysis)
  • affective disorder
  • confusion
  • agitation
  • restlessness
  • seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is also important to store it at room temperature, between 1 degree and 30 degrees Celsius, avoiding temperatures that are too hot or too cold.

Appearance and packaging

Appearance

Pale orange almond-shaped film-coated extended-release tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.